NCT02719613 - Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 15, 2016

Primary Completion Date

November 13, 2025

Study Completion Date

November 13, 2025

Conditions

Multiple Myeloma

Interventions

DRUG

Elotuzumab

Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.

DRUG

Dexamethasone

Patients will continue to receive treatment with non-investigational study drug by oral tablet administration at the last dose and schedule received in the previous study.

DRUG

Dexamethasone

Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.

DRUG

Lenalidomide

Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.

DRUG

Bortezomib

Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) or subcutaneous injection solution administration at the last dose and schedule received in the previous study.

DRUG

Pomalidomide

Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.

DRUG

Nivolumab

Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.

Trial Locations (41)

1097

Local Institution - 0036, Budapest

2060

Local Institution - 0023, Antwerp

3084

Local Institution - 0034, Heidelberg

10029

Local Institution - 0004, New York

10126

Local Institution - 0014, Torino

11528

Local Institution - 0035, Athens

16132

Local Institution - 0013, Genova

18015

Local Institution - 0001, Bethlehem

30322

Local Institution - 0009, Atlanta

32256

Local Institution - 0021, Jacksonville

33705

Local Institution - 0042, St. Petersburg

45004

Local Institution - 0030, Toledo

46260

Local Institution - 0003, Indianapolis

48121

Local Institution - 0043, Ravenna

50134

Local Institution - 0012, Florence

60126

Local Institution - 0015, Ancona

63110

Local Institution - 0008, St Louis

75231

Local Institution - 0018, Dallas

80218

Local Institution - 0019, Denver

85715

Local Institution - 0020, Tucson

90069

Local Institution - 0016, West Hollywood

92708

Local Institution - 0022, Fountain Valley

93309

Local Institution - 0017, Bakersfield

700483

Local Institution - 0029, Iași

3091793

Local Institution - 0045, Kasama-shi

3770280

Local Institution - 0047, Shibukawa-shi

5300012

Local Institution - 0049, Osaka

02215

Local Institution - 0002, Boston

M5G 2M9

Local Institution - 0011, Toronto

B3H 2Y9

Local Institution - 0010, Halifax

05100

Local Institution - 0044, Terni

0308553

Local Institution - 0046, Aomori

135-8550

Local Institution - 0048, Koto-ku

260-8677

Local Institution - 0050, Chiba

41-500

Local Institution - 0027, Chorzów

02-106

Local Institution - 0026, Warsaw

02-776

Local Institution - 0039, Warsaw

030171

Local Institution - 0028, Bucharest

08036

Local Institution - 0041, Barcelona

06620

Local Institution - 0031, Cebeci Ankara

EC1A 7BE

Local Institution - 0032, London